Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial)

被引：22
|
作者：
Chanan-Khan, A. [1 ]
Egyed, M. [2 ]
Robak, T. [3 ]
Martinelli de Oliveira, F. A. [4 ]
Echeveste, M. A. [5 ]
Dolan, S. [6 ]
Desjardins, P. [7 ]
Blonski, J. Z. [3 ]
Mei, J. [8 ]
Golany, N. [8 ]
Zhang, J. [8 ]
Gribben, J. G. [9 ]
机构：
[1] Mayo Clin, Div Hematol & Oncol, Jacksonville, FL 32224 USA
[2] Kaposi Mor Oktato Korhaz, Dept Internal Med, Kaposvar, Hungary
[3] Med Univ Lodz, Dept Hematol, Lodz, Poland
[4] Hosp Erasto Gaertner, Dept Oncol, Curitiba, Parana, Brazil
[5] Hosp Univ Donostia, Hematol Serv, San Sebastian, Spain
[6] St Johns Hosp, Div Hematol, St John, NB, Canada
[7] Hosp Charles LeMoyne, Dept Hematol, Greenfield Pk, PQ, Canada
[8] Celgene Corp, Summit, NJ USA
[9] Barts Canc Inst, Ctr Haemato Oncol, London, England
来源：
LEUKEMIA | 2017年 / 31卷 / 05期
关键词：
D O I：
10.1038/leu.2017.47
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1240 / 1243
页数：5
相关论文
共 50 条
  • [31] Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia
    Kater, Arnon P.
    van Oers, Marinus H. J.
    van Norden, Yvette
    van der Straten, Lina
    Driessen, Julia
    Posthuma, Ward F. M.
    Schipperus, Martin
    Chamuleau, Martine E. D.
    Nijland, Marcel
    Doorduijn, Jeanette K.
    Van Gelder, Michel
    Hoogendoorn, Mels
    De Croon, Francien
    Wittebol, Shulamiet
    Kerst, J. Martijn
    Marijt, Erik W. A.
    Raymakers, Reinier A. P.
    Schaafsma, Martijn R.
    Dobber, Johan A.
    Kersting, Sabina
    Levin, Mark-David
    HAEMATOLOGICA, 2019, 104 (01) : 147 - 154
  • [32] COST-EFFECTIVENESS OF OFATUMUMAB PLUS CHLORAMBUCIL IN FIRST-LINE CHRONIC LYMPHOCYTIC LEUKEMIA IN THE UNITED KINGDOM
    Pearson, I., V
    Hawe, E.
    Zuluaga, S.
    Wolowacz, S.
    Haiderali, A.
    VALUE IN HEALTH, 2015, 18 (07) : A455 - A455
  • [33] Rituximab as first-line and maintenance therapy for patients with small lymphocytic lymphoma (SLL) and chronic lymphocytic leukemia (CLL).
    Hainsworth, JD
    Litchy, S
    Burris, HA
    Greco, FA
    BLOOD, 2001, 98 (11) : 363A - 363A
  • [34] Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia
    Itchaki, Gilad
    Brown, Jennifer R.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2018, 9 (01) : 3 - 19
  • [35] Cholorambucil versus Cholorambucil Plus Prednisolone as First-Line Therapy of Chronic Lymphocytic Leukemia in West of Iran
    Payandeh, Mehrdad
    Sadeghi, Masoud
    Sadeghi, Edris
    IRANIAN JOURNAL OF CANCER PREVENTION, 2015, 8 (02) : 94 - 99
  • [36] Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia
    Lampson, Benjamin L.
    Kim, Haesook T.
    Davids, Matthew S.
    Abramson, Jeremy S.
    Freedman, Arnold S.
    Jacobson, Caron A.
    Armand, Philippe A.
    Joyce, Robin M.
    Arnason, Jon E.
    Rassenti, Laura Z.
    Kipps, Thomas J.
    Fein, Joshua
    Fernandes, Stacey M.
    Hanna, John R.
    Fisher, David C.
    Brown, Jennifer R.
    BLOOD ADVANCES, 2019, 3 (07) : 1167 - 1174
  • [37] Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia A Nonrandomized Phase 2 Trial
    Jain, Nitin
    Keating, Michael
    Thompson, Philip
    Ferrajoli, Alessandra
    Burger, Jan A.
    Borthakur, Gautam
    Takahashi, Koichi
    Estrov, Zeev
    Sasaki, Koji
    Fowler, Nathan
    Kadia, Tapan
    Konopleva, Marina
    Alvarado, Yesid
    Yilmaz, Musa
    DiNardo, Courtney
    Bose, Prithviraj
    Ohanian, Maro
    Pemmaraju, Naveen
    Jabbour, Elias
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Wang, Wei
    Jorgensen, Jeffrey
    Wang, Sa A.
    Garg, Naveen
    Wang, Xuemei
    Wei, Chongjuan
    Cruz, Nichole
    Ayala, Ana
    Plunkett, William
    Kantarjian, Hagop
    Gandhi, Varsha
    Wierda, William G.
    JAMA ONCOLOGY, 2021, 7 (08) : 1213 - 1219
  • [38] First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study
    Meunier, Godelieve
    Ysebaert, Loic
    Phi Linh Nguyen-Thi
    Lepretre, Stephane
    Quinquenel, Anne
    Dupuis, Jehan
    Lemal, Richard
    Aurran, Therese
    Tomowiak, Cecile
    Cymbalista, Florence
    Dilhuydy, Marie Sarah
    Brion, Annie
    Morel, Pierre
    Cazin, Bruno
    Leblond, Veronique
    Cartron, Guillaume
    Re, Daniel
    Bene, Marie Christine
    Michallet, Anne Sophie
    Feugier, Pierre
    HEMATOLOGICAL ONCOLOGY, 2017, 35 (04) : 671 - 678
  • [39] Updated Efficacy and Safety From the Phase 3 RESONATE-2 Study: Ibrutinib as First-Line Treatment Option in Patients 65 Years and Older With Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (12) : 16 - 17
  • [40] Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia
    Barr, Paul
    Robak, Tadeusz
    Owen, Carolyn J.
    Tedeschi, Alessandra
    Bairey, Osnat
    Bartlett, Nancy L.
    Burger, Jan
    Hillmen, Peter
    Coutre, Steven
    Devereux, Stephen
    Grosicki, Sebastian
    McCarthy, Helen
    Li, Jianyong
    Simpson, David
    Offner, Fritz
    Moreno, Carol
    Zhou, Cathy
    Styles, Lori
    James, Danelle F.
    Kipps, Thomas J.
    Ghia, Paolo
    BLOOD, 2016, 128 (22)
12345